To further elucidate the role of RTK-mutations in MM, we deep-sequenced the CDS of the RTKs EGFR, EPHA2, ERBB3, IGF1R, NTRK1 and NTRK2 that were found to be mutated in previous studies and investigated the association of these mutations with common cytogenetic alterations and clinical parameters in a study cohort of 75 patients of the DSMM that were uniformly treated with bortezomib, autologous stem cell transplantation and high dose chemotherapy. The gene discussed is NTRK1; the disease is Miyoshi myopathy.